Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
Rhea-AI Summary
Eyenovia, Inc. will release its financial results for Q1 2023 on May 11, 2023, after the markets close. The company will host an investor conference call and webcast at 4:30pm EDT to review the financial and operating results.
Positive
Eyenovia, Inc. will release its financial results for Q1 2023, which could positively affect investor sentiment and potentially lead to an increase in stock price.
05/04/2023 - 08:00 AM
Company to host an investor conference call and webcast at 4:30pm EDT
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.
Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international). A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com .
To access the Call me™ feature, which avoids having to wait for an operator, click here .
After the live webcast, the event will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com .
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations .
Eyenovia Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officerjgandolfo@eyenovia.com
Eyenovia Investor Contact: Eric Ribner LifeSci Advisors, LLCeric@lifesciadvisors.com (646) 751-4363
Eyenovia Media Contact: Eyenovia, Inc. Norbert Lowe Vice President, Commercial Operationsnlowe@eyenovia.com
Eyenovia will release its financial results for Q1 2023 on May 11, 2023, after the markets close.
Eyenovia will review its financial and operating results during the investor conference call and webcast.
The live webcast of the conference call will be available on Eyenovia's investor relations page on its corporate website at www.eyenovia.com.
Yes, the event will be archived on Eyenovia's website for one year after the live webcast.
EYEN Rankings
#4670 Ranked by Stock Gains
EYEN Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About EYEN
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.